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Abstract
Objective: To evaluate the effectiveness of whole-genome array comparative genomic hybridization (aCGH) in prenatal
diagnosis in Hong Kong.
Methods: Array CGH was performed on 220 samples recruited prospectively as the first-tier test study. In addition 150
prenatal samples with abnormal fetal ultrasound findings found to have normal karyotypes were analyzed as a ‘further-test’
study using NimbleGen CGX-135K oligonucleotide arrays.
Results: Array CGH findings were concordant with conventional cytogenetic results with the exception of one case of
triploidy. It was found in the first-tier test study that aCGH detected 20% (44/220) clinically significant copy number variants
(CNV), of which 21 were common aneuploidies and 23 had other chromosomal imbalances. There were 3.2% (7/220)
samples with CNVs detected by aCGH but not by conventional cytogenetics. In the ‘further-test’ study, the additional
diagnostic yield of detecting chromosome imbalance was 6% (9/150). The overall detection for CNVs of unclear clinical
significance was 2.7% (10/370) with 0.9% found to be de novo. Eleven loci of common CNVs were found in the local
population.
Conclusion: Whole-genome aCGH offered a higher resolution diagnostic capacity than conventional karyotyping for
prenatal diagnosis either as a first-tier test or as a ‘further-test’ for pregnancies with fetal ultrasound anomalies. We propose
replacing conventional cytogenetics with aCGH for all pregnancies undergoing invasive diagnostic procedures after
excluding common aneuploidies and triploidies by quantitative fluorescent PCR. Conventional cytogenetics can be reserved
for visualization of clinically significant CNVs.
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Introduction
Conventional cytogenetics has been the gold standard for
detecting chromosomal abnormalities in prenatal diagnosis. It
enables the examination of genome-wide numerical and structural
abnormalities at microscopic level, and can achieve a resolution of
5–10 Mb [1]. However, the method is labour intensive, with a
turn-around time of 14 to 21 days. Various molecular cytogenetic
techniques, such as Quantitative Fluorescent Polymerase Chain
Reaction (QF-PCR) [2,3] and Fluorescent In Situ Hybridization
(FISH) technology, could complement the detection of chromo-
somal abnormalities and offer faster turn-around times. However,
these methods are targeted to detect specific chromosomal
abnormalities and are dependent on the chromosomal probe
used. In contrast, whole-genome array comparative hybridization
(aCGH) not only provides high resolution detection of genomic
alterations, but also allows refinement of breakpoints on chromo-
some rearrangements.
Chromosomal microarray to assess DNA copy number varia-
tions has been suggested as the first-tier clinical diagnostic test in
the postnatal setting for individuals with developmental disabilities
or congenital anomalies because of an increased diagnostic yield of
12 to 15% compared to conventional karyotyping [4,5]. The
clinical utility of aCGH in the prenatal setting has been
demonstrated in systematic reviews [6–8], a large scale prospective
randomized controlled trial [9] and also in recent research [10].
The major challenge for the large-scale implementation of these
techniques appears to lie in interpretation of the results [11]. Thus
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genetic counseling and ethical issues [12,13] are significant in
offering whole-genome aCGH in prenatal diagnosis. Essentially,
there is a need for consensus in determining which patient groups
should be offered in routine prenatal practice, and international
guidance on interpretation and reporting of copy number
variations for prenatal population [11]. This evaluation study
demonstrates the advantages and disadvantages of aCGH and
argues that whole-genome oligonucleotide aCGH is able to
replace conventional cytogenetics in prenatal diagnosis in the
local population of Hong Kong.
In this study, the use of aCGH for prenatal diagnosis is
evaluated in two models: (1) as a first-tier test and, (2) as a ‘further-
test’ analyzing prenatal samples of patients with abnormal fetal
ultrasound findings and normal karyotypes. Results from aCGH
are compared with those from conventional cytogenetics in order
to determine the concordance of results and the additional
diagnostic yield of aCGH over karyotyping.
Methods
Patients and samples
Approval was granted by the Institutional Review Board,
University of Hong Kong/Hospital Authority, Hong Kong for the
study to be conducted within 3 hospitals: Tsan Yuk Hospital,
Queen Elizabeth Hospital, and Kwong Wah Hospital. Written
informed consent was obtained from participants, who were
recruited between January 2011 and November 2012. Informed
consent and counseling on the benefits and limitations of the test,
test methodology, reporting time, and possible test results
(clinically significant, unclear clinical significance, benign) and
outcomes of the investigation were explained to the participants by
medical staff. Parental blood samples were obtained at the time of
consent in case information on inheritance of CNV is necessary for
further interpretation of prenatal results. Prenatal samples of 370
patients (Figure 1) with indications for chromosome studies were
tested using whole-genome aCGH analysis at the Prenatal
Diagnostic Laboratory, Tsan Yuk Hospital. Of those 370 prenatal
samples, 220 patients had been prospectively recruited for the first-
tier test study prior to the invasive procedure. In addition, 150
subjects with abnormal fetal ultrasound findings were retrospec-
tively recruited into the ‘further-test’ study once conventional
cytogenetic results had shown a normal karyotype on invasive
testing. A total of 193 parental blood samples were used to
categorize unclear CNVs identified in the corresponding prenatal
samples in the evaluation study. In addition to the evaluation
study, abnormal findings of 12 prenatal samples tested by
conventional cytogenetics and requiring characterization were
assessed using aCGH.
Conventional cytogenetics was performed by Giemsa banded
(G-banded) karyotyping as a clinical service on all prenatal
samples at Prenatal Diagnostic Laboratory, Tsan Yuk Hospital. As
per protocol, optimally, 3–5 mg of dissected chorionic villi or
30 ml amniotic fluid was obtained to set up for karyotype, QF-
PCR and aCGH. Cultured cells in flasks were used when either a)
there were not enough cells in the primary sample, or b) in
retrospective samples for the ‘further-test’ study, or c) in
retrospective samples required for characterization studies. Eleven
placental tissue samples and 2 skin biopsy samples obtained from
pregnancies which were terminated after abnormal fetal ultra-
sound findings were processed for aCGH analysis.
Indications for recruitment to the study
Prenatal patients with clinical indications for further diagnoses
were recruited to the research study. The reasons included
abnormal findings on fetal ultrasound; positive Down syndrome
screening; or maternal anxiety concerning advanced maternal age,
family history of genetic disorder or previous child with anomalies.
Some patients met more than one of the indications for study. In
categorizing the indications as shown in Figure 1, ultrasound
abnormality preceded positive Down syndrome screening and in
turn over maternal anxiety.
Methods of DNA extraction
Cells were pelleted from 5 ml amniotic fluid by centrifugation at
4006g for 10 min. DNA was extracted by Gentra Puregene
Tissue Kit (QIAGEN, USA) following manufacturer’s instruction.
Uncultured chorionic villi, tissue or cultured cells were pelleted by
centrifugation at 30006g for 5 min, lysed in 300 ml of lysis buffer
(100 mM Tris, pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl)
with Proteinase K at final concentration of 2 mg/ml. The lysate
was incubated at 55uC overnight, added with 7 ml of RNase A
solution (Qiagen, USA) and incubated at 37uC for 60 to 120 min.
DNA was precipitated by the addition of 2.5 volume of cold 100%
ethanol, spooled, washed twice with 1 ml of 70% ethanol and air
dried. The DNA pellet was dissolved in Tris EDTA (TE) buffer
(10 mM Tris, 0.1 mM EDTA, pH 7.5). For the blood samples,
3 ml of EDTA blood were diluted to 9 ml with 1X PBS. The
diluted blood was overlaid onto 6 ml of Ficoll-Paque Plus (GE
Healthcare Life Sciences) and centrifuged at 6006g for 30 min.
The mononuclear cells at the interphase were transferred to a
fresh tube and washed twice with 15 ml of 1X PBS. Cells were
pelleted by centrifugation at 4006g for 10 min. The cells were
lysed in 1 ml of lysis buffer (100 mM Tris, pH 8.5, 5 mM EDTA,
0.2% SDS, 200 mM NaCl) and DNA was precipitated and
Figure 1. A schematic diagram showing the indications for
recruitment to the study and CNVs detected in the evaluation
study. The samples were subjected to first-tier test and ‘further-test’,
with the clinical indications of testing and findings stated. aCGH, array
CGH; CNVs, copy number variants; n, number of samples; DS +ve, Down
syndrome screening positive; USS abn, ultrasound abnormality; Anxiety:
maternal anxiety. Details on the clinically significant CNVs and CNVs of
uncertain clinical significance are listed in Tables 1, 2, 3, 4, 5, 6.
doi:10.1371/journal.pone.0087988.g001
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processed as above. Where DNA extraction was deemed urgent,
for example in advanced gestations, a commercial kit (QIAmp
DNA blood kit, Qiagen, USA) was used. The concentration of
DNA samples was measured by NanoDropND-1000 spectropho-
tometer (NanoDrop Technologies, USA) and the quality of DNA
samples was analyzed by agarose gel electrophoresis to exclude
degradation or RNA contamination.
Array CGH analysis and interpretation
All samples were tested by NimbleGen CGX-135K arrays
which were designed by Signature Genomics (Perkin Elmer, USA)
following manufacturer’s instructions. The coverage of the array
has an average resolution of 140 kb across the genome and 40 kb
or less in regions of clinical relevance. It evaluates over 245 known
genetic syndromes and over 980 gene regions of functional
significance in human development. The data were analyzed by
Genoglyphix software (Signature Genomics, Spokane, USA). The
gender of the prenatal samples was examined using QF-PCR [14]
to determine the gender-matched reference DNA used in aCGH.
The control DNA was from pooled gender-matched DNA from
Promega (Madison, Wisconsin, USA).
Copy number variants (CNVs) detected by aCGH were
systematically evaluated for clinical significance by comparison
with information in the Signature Genomics’ proprietary Geno-
glyphix Chromosome Aberration Database (Signature Genomics,
Spokane, WA, USA), the internal laboratory database at Tsan
Yuk Hospital, and the publicly available databases [Database of
Genomic Variant (DGV), International Standards for Cytoge-
nomic Arrays Consortium Database (ISCA), Children Hospital of
Philadelphia database (CHOP), Database of Chromosomal
Imbalance and Phenotype in Humans using Ensembl Resources
(DECIPHER)]. Categorization of CNVs was based on available
information concerning the fetal phenotypes and by comparison of
phenotypes with known genes in the region of copy gain or loss.
This was ascertained from searching Online Mendelian Inheri-
tance in Man (OMIM), PubMed, RefSeq and the University of
California Santa Cruz (UCSC) genome browser. A CNV was
considered to be: (1) benign if it was reported in healthy subjects in
the databases searched; if there are no genes involved; or if
involved genes were unrelated to the phenotype and have no
apparent clinical relevance; (2) clinically significant if it corre-
sponded to a region known to be of clinical relevance or had a
gene of clinical relevance; (3) of unclear clinical significance if there
is insufficient evidence to categorize as clinically significant or
benign at the time of reporting. When CNVs of unclear clinical
significance were detected in a prenatal sample, parental blood
samples were processed to provide additional information for
interpretation.
Confirmation of CNVs
Clinically significant copy number gains and losses not
detectable by karyotyping were confirmed by Fluorescent In Situ
Hybridization (FISH) studies whenever possible. Microdeletion
and telomeric FISH probes were obtained from Abbott Diagnos-
tics (USA) and FISH probes from bacterial artificial chromosome
clones from The Centre for Applied Genomics at the Hospital for
Sick Children (Toronto, Canada). Homozygous alpha thalassemia
deletion was confirmed by standard laboratory protocol [15].
Microarray data are available in the ArrayExpress database
(www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-
2156.
Results
Clinically significant CNVs identified by aCGH in the prenatal
samples from both the first-tier test study and from the ‘further-
test’ study are shown in Figure 1. The initial turn-around time for
aCGH was 8–10 days, while conventional cytogenetics took 14–21
days (data not shown).
First-tier test study
Two hundred and twenty prenatal samples were examined
using whole-genome aCGH methodology together with routine
culture for G-banded karyotyping with or without QF-PCR rapid
aneuploidy testing. One hundred and sixteen samples (52.7%)
were positive for Down syndrome screening with no apparent fetal
ultrasound anomalies at the time of testing; whilst 77 prenatal
samples (35.0%) had fetal ultrasound anomalies detected prior to
invasive prenatal diagnosis. Forty of these fetal malformations
concerned a single organ system and 37 had abnormalities
involving more than one organ system. In 27 prenatal samples
(12.3%), maternal anxiety was the clinical indication for invasive
testing and inclusion into the study (Figure 1).
Clinically significant CNVs were detected in 44 (20%) out of
220 samples (Table 1). Common aneuploidies were detected in 21
prenatal samples (9.5%) with six cases of trisomy 21; seven cases of
trisomy 18; four cases of trisomy 13; and four cases of monosomy
X. Twenty three prenatal samples (10.5%) had other chromo-
somal imbalances, as summarized in Table 2, 3, 4. There were 7
(3.2%) prenatal samples with CNVs detected by aCGH which had
been undetected by karyotyping (Table 2, Case no. 1–7). In 9
(4.1%) samples, aCGH revealed additional information over G-
banded karyotyping (Table 3, Case no. 8–16). These included 4
complex chromosomal rearrangements (Table 3, Case no. 8–11)
involving 2 or more chromosome segments not attributed to
unbalanced translocations, one additional marker chromosome
(Table 3, Case no. 12), 2 additional ring structures (Table 3, Case
no. 13 and 14), one mosaic ring chromosome 18 (Table 3, Case
no. 15) and one unbalanced translocation which aCGH helped to
define a small deletion in the derivative chromosome (Table 3,
Case no. 16). In 7 samples (3.2%), aberrations were detected both
by aCGH and karyotyping. These included 4 unbalanced
translocations (Table 4, Case no. 17–20), trisomies involving
chromosome 7 or 16 (Table 4, Case no. 21, 22) and one case with
terminal deletion of chromosome 13 was identified (Table 4, Case
no. 23). The result of the first-tier study showed an additional
diagnostic yield of 3.2% (7/220) for aCGH over conventional G-
banded karyotyping. One triploidy was not detected by aCGH.
The clinically significant results were analyzed and categorized
according to the clinical indications for the investigations. There
were six cases of patients who had screened positive for Down
syndrome without fetal ultrasound anomalies being evident
(Table 1). Three cases had common aneuploidies (one each of
trisomy 13, 18, 21) and the remaining three had other
chromosomal imbalances including ring structures and trisomy 7
(Table 3, Case no. 14, 15, and Table 4 Case no. 21). In 77
prospective samples with fetal ultrasound anomalies detected
(Table 1), 38 (49.4%) showed clinically significant chromosomal
imbalances. Of these, 18 were common aneuploidies (three
trisomy 13, six trisomy 18, five trisomy 21 and four monosomy
X). In addition, 20 had other chromosomal imbalances (Table 2,
Case no. 1–7, Table 3, Case no. 8–13, 16, Table 4, Case no. 17–
20, 22 and 23). Eleven out of the 20 cases had fetal ultrasound
anomalies in more than one organ system (including the neck and
body fluid, central nervous system, cardiovascular, craniofacial,
gastrointestinal, genitourinary, musculoskeletal, thoracic, or other
aCGH Evaluation for Replacing Prenatal Karyotype
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anomalies including intrauterine growth restriction). Where
invasive testing was indicated for maternal anxiety, no chromo-
somal imbalance was detected in the 27 samples studied.
Further-test study after normal karyotyping
In 150 patients with normal karyotyping and abnormal fetal
ultrasound findings, nine clinically significant CNVs were identi-
fied using aCGH. All of the patients had fetal ultrasound detected
anomalies in more than one organ system (Table 5). These
included one 1p32 microdeletion resulting in NFIA haploinsuffi-
ciency [16]; one 22q11.2 microdeletion, one deletion in chromo-
some 14 resulting in paternal uniparental disomy 14-like
phenotype; one 8p23.1 microdeletion; one unbalanced transloca-
tion detected after an apparent normal karyotype and four samples
with microdeletion in 16p13.3 resulting in Hemoglobin Bart’s
disease. With the exception of the unbalanced translocation which
was undetected on chorionic villus karyotyping, but identified by
aCGH of the amniotic fluid and cytogenetic study, the remaining
CNVs detected were ,5 Mb in size and submicroscopic, beyond
the detection resolution of conventional karyotyping. The
additional diagnostic yield of aCGH over conventional cytogenet-
ics was found to be 6%.
CNV of unclear clinical significance
The detection rate for CNVs of unclear significance identified
during the evaluation study using the 135 K whole-genome array
was 2.7% (10/370), with 1.4% (3/220) detected for the first-tier
test and 4.7% (7/150) for ‘further-test’ (Table 6). Six of these 10
samples had CNVs associated with microdeletions or microdupli-
cations with incomplete penetrance and variable expressivity
(Table 6, Case no. 1, 2, 4–7). Eight samples involved genes or loci
which may be associated with neurodevelopmental problems
(Table 6, Case no. 1–8). Two samples involved genes associated
with structural abnormalities of organ systems that may or may
not have relevance to the phenotype (Table 6, Case no. 7, 8). One
de novo microdeletion of 1q21.1 with susceptibility for thrombo-
cytopenia-absent radius (TAR) was classified as a CNV of unclear
significance having determined that the fetal radii were present on
the follow-up ultrasound scan (Table 6, Case no. 7). Where CNVs
of unclear clinical significance were identified, the incidence of de
novo CNVs was found to be 0.9% of the total in the study (3/370).
Characterization by aCGH on samples with abnormal
karyotypes
During the study period, in addition to the 370 samples for the
evaluation study, twelve prenatal samples were identified with
abnormal karyotypes during conventional cytogenetics. These
were further examined by aCGH. Breakpoints were established for
two samples with unbalanced translocations and three samples
with interstitial deletions. One sample used aCGH to confirm
suspected deletion of chromosome 16 pter which had been
undetermined by G-banding. This sample was found to have a
balanced translocation between chromosome 2 and chromosome
10 which was inherited from the father. It was reassuring that no
submicroscopic changes were evident. Three samples showed
complex rearrangements, one involved a marker chromosome
derived from chromosome X, one involved a marker chromosome
derived from chromosome 15 which had the same array findings
as Case no. 8 in Table 3. One complex chromosomal rearrange-
ment involved translocation of a 1.76 Mb segment from chromo-
some 19 to a duplicated segment of chromosome 2. These three
complex rearrangements would not have been accurately detected
by conventional karyotyping.
Common benign CNVs
A total of 563 samples (370 prenatal and 193 parental) were
performed using aCGH for the first-tier test, ‘further-test’ studies
and for abnormal chromosomal characterization. These studies
established common benign CNVs at eleven loci in patients of
Hong Kong (Table 7). The most common locus with chromo-
somal gain or loss found in Hong Kong was at 8p11.23, and was
detected at a frequency of up to 78% (Table 7, no. 5) reflecting the
homogeneity of the local population. The proportion of parental
samples required to be performed was 144 out of 193 (74.6%) in
the first half period of evaluation and 49 out of 193 (25.4%) in the
second half. The knowledge of common benign CNVs in the local
population reduced the need for parental sample testing and could
minimize cost if aCGH use in prenatal diagnosis is launched as
clinical service.
Increased nuchal translucency (NT)
Among all 382 prenatal samples, 27 of them had NT of 3.5 mm
or above. In seven of these 27 prenatal samples Down syndrome
screening results were not available. The remainders were screened
positive for Down syndrome. There were three findings of trisomy
21, in addition to three samples with clinically significant CNVs
detectable by karyotyping. There were three samples with CNVs of
unclear clinical significance (Table 6, Case no. 3, 4, 6), one of which
had structural abnormality on fetal ultrasound scan. Therefore
aCGH did not yield increased detection of clinically significant
CNVs compared to karyotyping in this specific number of samples
with increased nuchal translucency.
Discussion
This evaluation study demonstrated the effectiveness of the
whole-genome oligonucleotide aCGH in prenatal diagnosis for the
Table 1. Clinically significant CNVs detected in the first-tier test study.
Clinically significant CNV*
Indication Samples Common aneuploidies (%) Other abnormalities (%) Total (%)
DS positive (no USS abn) 116 3 (2.6) 3 (2.6) 6 (5.2)
USS abn 77 18 (23.4) 20 (26.0) 38 (49.4)
Anxiety 27 0 0 0
Total 220 21 (9.5) 23 (10.5) 44 (20.0)
DS: Down syndrome screening; USS abn: ultrasound abnormality;
*percentage of clinical significant CNV found in the indication category.
doi:10.1371/journal.pone.0087988.t001
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analysis of chromosome imbalance at high resolution. During the
first-tier test, a detection rate of 20% was determined amongst
patients with clinical indications for testing. Clinically significant
imbalances were found to be common aneuploidies (9.5%), whilst
10.5% involved other chromosomal abnormalities (Table 1).
Rapid aneuploidy testing such as QF-PCR is able to exclude
common aneuploidies prior to testing using aCGH. This would
make aCGH more cost effective. Scott et al. also proposed the use
of combined QF-PCR and aCGH as first-line prenatal diagnostic
testing [17]. Our detection rate of 10.5% clinically significant
CNVs other than common aneuploidy was double that of Scott
et al. (2013). It is considered that this may be related to different
patient characteristics, different indications for prenatal testing, in
addition to using whole-genome rather than targeted array. CNVs
only detectable by aCGH were also higher in our evaluation study
(3.2% in this study versus 1.2% pathogenic CNVs) [17].
Array CGH helped to precisely delineate breakpoints, charac-
terize marker chromosomes and detect mosaicism within a shorter
time frame compared to G-banded cytogenetics. There were five
samples with chromosome mosaicism in the study. Mosaic trisomy
19 and mosaic trisomy 7 (Table 2, Case no. 2 and Table 4 Case
no. 21) were results confined to placental mosaicism where studies
on skin fibroblast and in the amniotic fluid sample respectively
indicated normal karyotypes. Of interest was a mosaic ring
chromosome 18 finding with aCGH of one copy number gain for
the chromosome 18 segment (Table 3, Case no. 13), not matching
the mosaic ratio, but the FISH study found a small number of
double rings in the cell population which explained the array
result.
Four complex chromosomal rearrangements were determined
in the first-tier test study, and three complex rearrangements were
identified from prenatal samples with abnormal karyotypes
requiring characterization. This highlighted the advantage of
higher resolution aCGH in chromosome analysis. There were two
samples with identical complex rearrangement comprising 2-copy
gain at the Prader Willi/Angelman syndrome region (15q11.2–
q13.2) and one copy gain at the 15q13.3 Microdeletion region
(15q13.2–q13.3, Figure 2). Karyotyping of the first sample
(Figure 2 Sample A; Table 3, Case no. 8) showed 15q+ while
the chromosomal gain in the second sample (Figure 2 Sample B)
performed using aCGH for characterization was in a marker
chromosome. Although aCGH showed the same chromosomal
imbalances, the phenotypes of the 2 samples were very different.
In the latter sample choroid plexus cyst was the only anomaly.
Since other CNVs detected in Case no. 8 (Table 3) were benign
and apparently common in the local population, the severe
phenotype may have been caused by small mutation in another
chromosomal region or an interruption of the region 15q11.2–
q13.2 by a complex rearrangement. The 15q proximal region is
known for its instability due to the presence of repeating DNA
elements [18,19] which may give rise to the triplication from
centromere to breakpoint (BP) 4 plus duplication from BP4 to BP5
in these samples. Further investigation into the association of
phenotypes and the manifestation of the copy number gain and
imprinting [20] can be made on similar samples with rearrange-
ments in the region. The finding also demonstrated the advances
of complementary use of both aCGH and karyotyping in
analyzing samples with multiple significant CNVs.
There were 4 cases of Hemoglobin Bart’s disease with clinically
significant aCGH findings in the ‘further-test’ study. While routine
prenatal screening for thalassaemia by mean corpuscular volume
(MCV) is offered in our locality, one case presented late in the third
trimester (Table 5,Case no. 9) andwas a result of non-paternity.This
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highlighted one potential use of the test to diagnose Hemoglobin
Bart’s disease in circumstances of non-paternity [21].
Uncertain CNVs tend to be a concern for clinicians in counseling.
Adequate pre and post-test information and counseling by trained
counselors, and a team approach involving obstetricians, clinical
geneticists and laboratory scientists in CNV interpretation is
beneficial and is adopted in our setting. In this evaluation study,
both CNVs of clinical significance and CNVs of unclear significance
were reported to referring doctors. In the 10 cases with CNVs of
unclear clinical significance, 5 of the pregnancies, all with major
ultrasound abnormalities, were terminated (Table 6). Maternal cell
contamination was not determined during the evaluation study.
However the impact of contamination on the interpretation of
prenatal microarray has been reported [22]. Taking this into
account, our laboratory has adopted the policy to routinely exclude
Table 7. Common benign CNVs found in Hong Kong.
No. Region size (Kb) Cytoband Location Genome coordinates Event Genes
Frequency of gain/
loss (% )
1 194 1q31.1 chr1:187592011–187776739 Loss 0 9
2 37 1q44 chr1:246644054–246914515 Gain/Loss 1 29/13
3 122 6p25.3 chr6:210793–321392 Gain/Loss 1 7/18
4 171 7p22.3 chr7:136,363–325,833 Gain 0 14
5 97–125 8p11.23 chr8:39310297–39531197 Gain/Loss 1–2 51/27
6 68–504 14q11.2 chr14:21388121–22089869 Gain/Loss 0–2 23/12
7 3–180 16p12.1 chr16:22534936–22689740 Gain/Loss 0 1/11
8 320 17q21.31 chr17:41507230–42147712 Gain/Loss 1 2/55
9 83 19p12 chr19:20408868–20518856 Loss 0 20
10 123 Xp22.33 chrX:3761569–3863478 Gain/Loss 1 9/34
11 105–109 Xq28 chrX:153064828–153168166 Gain/Loss 3 23/9
Kb: Kilobase.
doi:10.1371/journal.pone.0087988.t007
Figure 2. Identical complex chromosomal rearrangements in chromosome 15 found in 2 prenatal samples with different
karyotypes and phenotypes. Sample A karyotype is 46,XY,15q+ dn (Table 3, Case no. 8); Sample B karyotype is 47,XX,+mar from characterization
study. Each dot on the X-axis represents one oligonucleotide probe on the respective chromosome position. Two-copy gain is detected at
15q11.2q13.2 with minimum gain of 7.77 Mb. Single copy gain is detected at 15q13.2q13.3 with minimum gain of 1.3 Mb. No probe is located in the
segment between the 2 regions of copy gains, therefore the exact number of copy gained is unknown in the segment. The genetic syndromes (red
boxes) and genes (green boxes) in the region denoted by Signature Genomics Genoglyphix software are shown in the lower panel.
doi:10.1371/journal.pone.0087988.g002
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maternal cell contamination by examining STR markers of 13, 18
and 21 in fetal and maternal samples.
Various authorities already approved the offering of aCGH as
an adjunct diagnostic tool in prenatal cases with fetal ultrasound
abnormalities [23–24]. The additional diagnostic yield of 6% in
our further-test study is consistent with 5.2 to 10% increased
detection by aCGH in fetuses with ultrasound abnormalities and
normal karyotype reported in the literature [6,7]. Data from a
review study showed the overall detection rate of about 1% for
significant submicroscopic aberrations in low risk pregnancies
[10]. This consequently caused microarrays to be identified as a
first-line diagnostic test in women choosing the test irrespective of
clinical indication [9,10,25]. This is in line with the latest
recommendations from the American College of Obstetricians
and Gynecologists and the Society of Maternal-Fetal Medicine
[26]. Based on these findings and reports in the literature [6–
10,25] on the potential of aCGH to detect chromosomal
abnormalities beyond G-banded karyotyping, it is proposed that
whole-genome aCGH would be suitable to replace conventional
cytogenetics in prenatal diagnosis in Hong Kong (Figure 3). In a
prenatal diagnostic setting, women screened positive for fetal
Down syndrome may be offered an option of having noninvasive
prenatal testing for fetal trisomy assessment by maternal plasma
DNA if there is no ultrasound abnormality. In cases where
ultrasound examination shows fetal abnormalities which require
additional information from aCGH, an invasive diagnostic test
could be performed. Rapid aneuploidy testing of the sample with
QF-PCR would exclude common aneuploidies, triploidy and
maternal contamination before aCGH analysis. This rapid test
would identify triploidy which cannot be identified by aCGH.
Cultures would be set up for cytogenetic study and karyotyping for
all clinically significant CNVs (20.0%, Table 1) detected by aCGH
if the CNV is large (.10 Mb). In cases where the CNV is small
(,10 Mb), metaphase and interphase FISH could be performed.
Conventional cytogenetics performed for abnormal QF-PCR
findings (9.5% of samples, Table 1) would be needed to assess
whether there is a parental balanced translocation carrier state in
order to determine recurrence risk. This approach would reduce
conventional cytogenetic testing by around 80% of the cases in
Hong Kong. The disadvantages would include the potential for
non-detection of balanced translocation or an inversion carrier
status, low level mosaicism or small heterochromatic marker
chromosomes of the fetus. Whilst non-detection of balanced
translocation or inversion carrier status would be unlikely to affect
the health of the fetus, low level mosaicism detection is a limitation
of all prenatal investigation techniques. Further cost-benefit
analysis and review of the staffing requirements of a cytogenetic
laboratory may help to define the value of using microarrays for
our prenatal diagnostic service provision.
NimbleGen has, however, phased out production of oligonu-
cleotide 135 K arrays in favor of transitioning to Agilent
oligonucleotide 8660 K array, which has a lower backbone
resolution. It is therefore anticipated that fewer CNVs of unclear
significance will be detected for prenatal samples, with a shorter
hybridization and faster turn-around time expected. Further
studies will be required to confirm these effects.
Conclusions
This evaluation study showed that the whole-genome 135 K
aCGH platform increased the diagnostic yield of 3.2% using
aCGH over conventional cytogenetics in the first-tier test study,
and by 6.0% in the ‘further-test’ study for the Hong Kong
population. It also offered a higher resolution karyotyping for
prenatal diagnosis in both study models and results are compa-
rable to recent published studies. It is proposed that aCGH should
replace karyotyping for use in prenatal testing where invasive
procedures are required, after excluding common aneuploidies
and triploidies by quantitative fluorescent PCR. Conventional
cytogenetics can be reserved for visualization of clinically
significant CNVs.
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